艾米洛性白血病患者中,米普莱塔米格与维尼托克拉克斯和阿扎西提丁联合治疗的效果强,临床效益为86%,没有细胞因子释放综合征. Mipletamig with venetoclax and azacitidine showed strong results in elderly AML patients, with 86% clinical benefit and no cytokine release syndrome.

据Aptevo Therapeutics报告,RAINIER试验的中间结果显示,在新诊断的急性髓性白血病的老年或不适合治疗的患者中,Mipletamig与venetoclax和azacitidine联合治疗的临床效益率为86%. Aptevo Therapeutics reports interim RAINIER trial results showing that mipletamig combined with venetoclax and azacitidine achieved an 86% clinical benefit rate in elderly or unfit patients with newly diagnosed acute myeloid leukemia. 在28个可评价的病人中,没有出现细胞外泄综合症病例,55%的病人实现了完全或部分的缓解,并患有可计量的残余疾病。 Among 28 evaluable patients, no cases of cytokine release syndrome occurred, and 55% achieved complete or partial remission with measurable residual disease negativity. 4名病人进行了异源干细胞移植,这是这一组人中罕见的事件。 Four patients proceeded to allogeneic stem cell transplant, a rare event in this group. 治疗显示出一种有利的安全特征,包括在具有高风险TP53突变的人群中。 The treatment showed a favorable safety profile, including in those with high-risk TP53 mutations. 正在进行的第1b/2阶段的试验继续使病人入学。 The ongoing Phase 1b/2 trial continues to enroll patients.